Tuesday, September 22, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchsemaglutideorforglipronnaiondiabetic retinopathy

Review ties NAION signal to high-exposure subcutaneous semaglutide

Reported hazard ratios ranged from 1.29 to 7.64 for optic neuropathy, with authors proposing a preliminary steady-state concentration threshold of 30 to 55 nmol/L.

PR
By Priya Raman · Science Reporter
Sep 6 20:00 ETSource: Biomolecules & biomedicine

The wire

  1. 01The narrative review of PubMed literature through June 2026 found the most consistent non-arteritic anterior ischemic optic neuropathy signal with high-exposure subcutaneous semaglutide, while oral semaglutide, liraglutide, dulaglutide, exenatide and tirzepatide data were absent or inconsistent.
  2. 02Retinopathy worsening appeared linked to rapid HbA1c drops of at least 2% rather than a class effect, supporting individualized ocular risk assessment rather than class-wide prescribing limits.
  3. 03Authors flag semaglutide 7.2 mg, with estimated steady-state concentration near 230 nmol/L, and oral orforglipron for formulation-specific postmarketing surveillance; direct NAION evidence for those agents is unavailable.

From the source

GLP-1 receptor agonists and ocular safety- Pharmacokinetic insights into ischemic optic neuropathy and diabetic retinopathy risk: A review

Biomolecules & biomedicine · 2026 Sep 7 · Malluhi M, Al-Naemi A, Akhtar S et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42770962/